Basic Information
| LncRNA/CircRNA Name | FEZF1-AS1 |
| Synonyms | NR_036484 |
| Region | GRCh38_7:122303658-122310077 |
| Ensemble | ENSG00000230316 |
| Refseq | NR_036484 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, Western blot, etc. |
| Sample | The human HCC cells( HepG2, SK-hep1, Huh7, HCCLM3), normal liver cell line (LO2) |
| Expression Pattern | up-regulated |
| Function Description | In conclusion, the present study for the first time demonstrated that FEZF1-AS1 serves as an oncogenic lncRNA in human HCC and implicated FEZF1-AS1 as a valuable therapeutic target for HCC treatment. Kaplan-Meier analysis of overall survival (OS) in 139 HCC patients based on FEZF1-AS1 expression. |
| Pubmed ID | 29957463 |
| Year | 2018 |
| Title | Long non-coding RNA FEZF1-AS1 promotes cell invasion and epithelial-mesenchymal transition through JAK2/STAT3 signaling pathway in human hepatocellular carcinoma. |
External Links
| Links for FEZF1-AS1 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |